Get the Stockscreener App
10.12
4.98%
-0.53
Exozymes Inc stock is traded at $10.12, with a volume of 7,479.
It is down -4.98% in the last 24 hours and down -40.12% over the past month.
See More
Previous Close:
$10.65
Open:
$10.53
24h Volume:
7,479
Relative Volume:
1.28
Market Cap:
$101.48M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-19.75%
1M Performance:
-40.12%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$10.05
$11.07
1-Week Range:
$9.75
$12.30
52-Week Range:
$9.75
$22.63
Exozymes Inc Stock (EXOZ) Company Profile
Name
Exozymes Inc
Sector
Industry
Phone
(626) - 415 - 1488
Address
750 ROYAL OAKS DR, MONROVIA
Compare EXOZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXOZ
Exozymes Inc
|
10.12 | 101.48M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Exozymes Inc Stock (EXOZ) Latest News
eXoZymes Inc. Reports 2024 Progress and IPO Success - TipRanks
eXoZymes appoints new chief commercial officer By Investing.com - Investing.com Canada
eXoZymes appoints new chief commercial officer - Investing.com
eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO - GlobeNewswire
Strategic Win: eXoZymes Taps 20-Year Biotech Leader to Drive Commercial Growth - Stock Titan
eXoZymes Provides Fourth Quarter and Full Year 2024 Update - GlobeNewswire
eXoZymes Unveils AI-Powered Enzyme Breakthrough in First Earnings Since Nasdaq Debut - Stock Titan
MDB Capital's Remarkable Growth: AUM Soars 2100%, New Platform Launch Drives Expansion - Stock Titan
New to The Street Show #639 Premieres Nationwide on Bloomberg Television, March 29 at 6:30 PM EST Featuring BioVie, Roadzen, Tonix Pharma, and eXoZymes Inc. - ACCESS Newswire
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
eXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025 - GlobeNewswire
AI Enzyme Pioneer EXOZ Reveals 2024 Financial Performance: Q4 Earnings Call Details - Stock Titan
New to The Street’s FOX Business Show #638 Spotlights Visionary CEOs and Breakthrough Innovations Across Health, AI, and Insurance Featuring BioVie CEO Cuong Do, Roadzen CEO Rohan Malhotra, Lou Basenese’s The Big Skinny on eXoZymes, and B - The State
New to The Street's FOX Business Show #638 Spotlights Visionary CEOs and Breakthrough Innovations Across Health, AI, and Insurance Featuring BioVie CEO Cuong Do, Roadzen CEO Rohan Malhotra, Lou Basenese's The Big Skinny on eXoZymes, and B - ACCESS Newswire
MDB Capital's 2024 Financial Results: CEO to Reveal Full Year Performance and Strategic Outlook - StockTitan
Who's Winning the AI Data Center Patent Race? New Report Reveals Surprising Leader - StockTitan
New to the Street Airs Show #630 on Fox Business Network Tonight at 10:30 PM PST Featuring Roadzen ($RDZN), BioVie ($BIVI), AtlasClear (ATCH), eXoZymes ($EXOZ), and EvolveHealthandLifestyle. - Markets Insider
New to the Street Airs Show #630 on Fox Business Network Tonight at 10:30 PM PST Featuring Roadzen ($RDZN), BioVie ($BIVI), AtlasClear (ATCH), eXoZymes ($EXOZ), and EvolveHealthandLifestyle.com With Craig Bruce - Corsicana Daily Sun
New to the Street Airs Show #630 on Fox Business Network Tonight at 10:30 PM PST Featuring Roadzen ($RDZN), BioVie ($BIVI), AtlasClear (ATCH), eXoZymes ($EXOZ), and EvolveHealthandLifestyle.com With C - StreetInsider
eXoZymes president, chairman Hayat transitions out of roles - MSN
EXoZymes, Inc. Announces Management Changes -February 21, 2025 at 04:37 pm EST - Marketscreener.com
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
ExoZymes Inc. appoints new board member and chairman By Investing.com - Investing.com Nigeria
eXoZymes Announces Leadership Changes with New Appointments - TipRanks
eXoZymes and MDB Capital Announce Leadership Transition at - GlobeNewswire
ExoZymes Inc. appoints new board member and chairman - Investing.com
eXoZymes Inc. Announces Leadership Changes and Rebranding Following Transition from Invizyne Technologies - Nasdaq
eXoZymes and MDB Capital Announce Leadership Transition at eXoZymes Inc. - GlobeNewswire
Exozymes (EXOZ) Income Statement & Balance Sheet 2025 - MarketBeat
eXoZymes Inc Rings the Nasdaq Stock Market Closing Bell - Nasdaq
eXoZymes Inc Rings the Closing Bell - Nasdaq
Reynolds Consumer Products, Inc Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Biotech’s New Frontier: Discover the “Exozymes Era” Revolutionizing Chemical Production - Mi Valle
The Dawn of an Era: eXoZymes Ushers in a New Age of Biotechnology - Jomfruland.net
eXoZymes Announces Nasdaq Bell Ringing to Commemorate Initial Public Offering - GlobeNewswire
Can This AI-Powered Enzyme Company Transform the Future of Biotech? Nasdaq's Newest IPO Makes Bold Claims - StockTitan
Decibel Expands General Admission Brand's International Footprint - The Globe and Mail
Triller Group Inc Rings the Nasdaq Stock Market Opening Bell - Nasdaq
3 Travel Stocks That Show the Travel Boom Is Far from Over - The Globe and Mail
Semtech Shares Plummet on AI Server Woes—Is a Turnaround Ahead? - The Globe and Mail
Analysts See Buying Opportunity in NVIDIA Before Earnings - The Globe and Mail
Prediction: ASML Will Beat the Market. Here's Why. - The Globe and Mail
3 Consumer Staples ETFs for Stability in a Volatile Market - The Globe and Mail
GCL Global Holdings Ltd. Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Positive week for Invizyne Technologies, Inc. (NASDAQ:EXOZ) institutional investors who control 42% of the company - Simply Wall St
Invizyne Technologies, Inc. will Change its Name to eXoZymes, Inc -February 12, 2025 at 12:00 am EST - Marketscreener.com
Invizyne Technologies, Inc. will Change its Ticker to EXOZ from IZTC -February 12, 2025 at 12:00 am EST - Marketscreener.com
Should You Forget AMD and Buy 2 Tech Stocks Instead? - The Globe and Mail
What’s in a Name: Out with Invizyne, In with eXoZymes - Genetic Engineering & Biotechnology News
Rebranding Invizyne to eXoZymes Signifies a Sustainable - GlobeNewswire
From Lab to Factory: AI-Engineered 'Exozymes' Promise Weeks-Fast Chemical Production Revolution - Stock Titan
Exozymes Inc Stock (EXOZ) Financials Data
There is no financial data for Exozymes Inc (EXOZ). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):